Every analyst, fund manager and economist who has been on ausbiz. Open an expert to see all of their videos, or follow them to get new ones in My ausbiz.
Kate Quirke is the Group Managing Director and CEO of Alcidion Group, bringing over 25 years of experience in digital health and healthcare technology. She has led major healthcare IT projects across Australia, New Zealand, the UK and South-East Asia, with expertise in business strategy, product development and digital health transformation. Kate also serves as a Non-Executive Director of ANDHealth and has received several industry leadership awards.
Jason Segal is the Founder and Analyst at The Armchair Analyst, an investment newsletter focused on making small-cap biotech investing more accessible to everyday investors. Previously, he spent six years at Next Investors, where he covered emerging ASX companies across the resources and biotech sectors.
Huw DaviesFounding Partner & Portfolio ManagerGrey Street Partners
"Huw brings over 20 years of extensive experience in financial services, having worked with leading global investment banks such as HSBC and Deutsche Bank. He specializes in thematic areas including the green energy transition, digital transformation, emerging consumer behaviors, and disruptive healthcare. His expertise in identifying growth opportunities within these transformative sectors has been instrumental in managing global growth funds, hedge funds, multi-asset growth portfolios, and a global growth SMA."
John is a senior sell side analyst at Bell Potter Securities in Sydney . He specialise in small and mid cap healthcare stocks, however, has also followed a wide variety of stocks over 10 years in the securities industry. These range from small biotechs to very large multinationals.. His deep know knowledge of complex stocks including Mayne Pharma, Medibank Private, Sirtex Medical and Viralytics have earned wide recognition from clients during course of 2015 and 2016. In addition to the fundamentals around capital structure and balance sheet strength, he looks for one or more of the following characteristics in a stock: Normally the CEO has had an integral part in establishing the company or providing outstanding vision. Scott Richards at Mayne Pharma and George Saviddes (former CEO of MPL) are good examples. "I take a great deal of confidence from a CEO who has grown with the company and is clever enough to surround himself with an experienced team". Secondly, if it is a technology or biotech stock, the science has to stack up. "I generally steer clear of stocks where there is an absence of solid evidence from clinical trial data. This rules out a lot of start ups and early stage c
Thomas WakimHealthcare Equity Research AnalystBell Potter
Thomas Wakim is a Sydney-based healthcare investment analyst at Bell Potter Securities, specialising in the biotechnology and healthcare sector. With a background in science from UNSW, Thomas brings a strong understanding of clinical research, emerging therapies, and the investment landscape to his work. He regularly provides insights into innovative healthcare companies and developments across areas including oncology, radiotherapeutics, and biotechnology. He has also been featured in industry discussions and interviews covering healthcare markets and emerging investment opportunities.
David LawsonChief Financial Office and the Company SecretaryCompumedics
Mr. Lawson has been Chief Financial Office and the Company Secretary of the Company for over nineteen years. In that time, Mr. Lawson has been extensively involved in the development of the Company including the Initial Public Offering of shares in the Company, the subsequent offshore acquisitions in the US and Germany, private equity placements and the recent refinancing of the Company. Mr. Lawson also has been involved in the operational turn around of the Company and brings a significant amount of experience and knowledge to the Board.
David has been Chief Executive Officer since May 2021. He has over 25 years of leadership experience across Australia, Asia and the UK, including previous work in the aviation, consulting and financial services industries. David joined Medibank in 2014 as Chief Operating Officer and then Group Executive – Chief Customer Officer from September 2016, responsible for the Medibank and ahm Health Insurance and Wellbeing portfolios. Relevant other directorships: Chair – Council of Management for the International Federation of Health Plans Relevant former directorships/executive roles: Group Chief Commercial Officer – Jetstar Director – Jetstar Pacific (Vietnam); NewStar airline group (Singapore) Non-Executive Director – Luxury Escapes
Sarah Thom is the CFO of Cochlear and is passionate about work that helps make people’s lives better. She serves on the Board of Children’s Medical Research Foundation and is a member of Chief Executive Women. She has deep experience defining and delivering large-scale change and innovation across complex organisations and ecosystems, with recognised expertise in strategy development and delivery, major investment evaluation and whole-of-business transformation.
A co-founder of Pro Medicus Limited in 1983, Dr Sam Hupert is a Monash University Medical School graduate who commenced Medical Practice in 1980. Realizing the significant potential for computers in medicine he left general practice in late 1984 to devote himself full time to managing the Company. He oversaw a strong period of growth in the company’s earnings from the listing on the ASX in 2000 until October 2007 when he retired as Managing Director and Chief Executive, to become Deputy Chairman and an Executive Director, maintaining an active role in the company. In October 2010, Dr. Hupert resumed his role as CEO, a position he previously held for 25 years.
Paul Gavin is the Chief Executive Officer at Avecho Biotechnology, bringing expertise backed by a Doctor of Philosophy. Their background reflects a strong focus on biotechnology and pharmaceutical innovation. Paul's leadership steers Avecho's strategic direction within the pharmaceutical sector. Drawing on a background in scientific research, they previously served as Chief Scientific Officer at Avecho Biotechnology. In this role, Paul provided scientific oversight and managed research initiatives. Prior to this, activities involved serving as Vice President, Research & Development, contributing to product development and innovation strategy. Paul's academic foundation includes a Doctor of Philosophy and a Bachelor of Science from Monash University
Jason CarrollCEO & Executive DirectorEntropy Neurodynamics
With 34 years of experience in the healthcare industry, Jason is a professional, experienced and highly successful leader who has delivered superior performance and high-functioning teams across four different countries and multiple healthcare categories. He is currently the CEO & Managing Director of Tryp Therapeutics, based in Sydney, Australia. In his previous role, as Managing Director of iNova Pharmaceuticals Philippines, iNova was the fastest growing multinational pharmaceutical company in the Country over a 5 year period, tripling sales and quadrupling profit and, was awarded by Nicholas Hall for the Best Digital Marketing Launch Globally for DIFFLAM FORTE Throat Spray in 2019. Jason's core competencies include Strategic Market insight, Licensing & Acquisition, Program Development & Execution, Customer Relationship Development for the long term, Sales, Marketing, Product Development, Pharmaceutical Manufacturing as well as a unique skillset in identifying and promoting Talent Development. Jason utilises his skills (testing higher than 99.9% vs global population) in Abstract Reasoning and Numerical Analysis in order to build unique and lateral insight, response and superior r
Experts’ views are their own and general in nature. They are not recommendations by ausbiz or ausbiz Invest, and experts may hold the investments they discuss. Consider your own circumstances and get professional advice.
We value your privacy
We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy